{"id":"NCT01763866","sponsor":"Amgen","briefTitle":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","officialTitle":"A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-15","primaryCompletion":"2013-11-12","completion":"2013-12-04","firstPosted":"2013-01-09","resultsPosted":"2015-12-22","lastUpdate":"2022-11-08"},"enrollment":2067,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperlipidemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"type":"DRUG","name":"Ezetimibe","otherNames":["Zetia"]},{"type":"DRUG","name":"Placebo to Evolocumab","otherNames":[]},{"type":"DRUG","name":"Placebo to Ezetimibe","otherNames":[]},{"type":"DRUG","name":"Atorvastatin","otherNames":["Lipitor"]},{"type":"DRUG","name":"Rosuvastatin","otherNames":["Crestor"]},{"type":"DRUG","name":"Simvastatin","otherNames":["Zocor"]}],"arms":[{"label":"A10 PBO Q2W","type":"PLACEBO_COMPARATOR"},{"label":"A10 PBO QM","type":"PLACEBO_COMPARATOR"},{"label":"A10 EZE (Q2W)","type":"ACTIVE_COMPARATOR"},{"label":"A10 EZE (QM)","type":"ACTIVE_COMPARATOR"},{"label":"A10 EvoMab Q2W","type":"EXPERIMENTAL"},{"label":"A10 EvoMab QM","type":"EXPERIMENTAL"},{"label":"A80 PBO Q2W","type":"PLACEBO_COMPARATOR"},{"label":"A80 PBO QM","type":"PLACEBO_COMPARATOR"},{"label":"A80 EZE (Q2W)","type":"ACTIVE_COMPARATOR"},{"label":"A80 EZE (QM)","type":"ACTIVE_COMPARATOR"},{"label":"A80 EvoMab Q2W","type":"EXPERIMENTAL"},{"label":"A80 EvoMab QM","type":"EXPERIMENTAL"},{"label":"R5 PBO Q2W","type":"PLACEBO_COMPARATOR"},{"label":"R5 PBO QM","type":"PLACEBO_COMPARATOR"},{"label":"R5 EvoMab Q2W","type":"EXPERIMENTAL"},{"label":"R5 EvoMab QM","type":"EXPERIMENTAL"},{"label":"R40 PBO Q2W","type":"PLACEBO_COMPARATOR"},{"label":"R40 PBO QM","type":"PLACEBO_COMPARATOR"},{"label":"R40 EvoMab Q2W","type":"EXPERIMENTAL"},{"label":"R40 EvoMab QM","type":"EXPERIMENTAL"},{"label":"S40 PBO Q2W","type":"PLACEBO_COMPARATOR"},{"label":"S40 PBO QM","type":"PLACEBO_COMPARATOR"},{"label":"S40 EvoMab Q2W","type":"EXPERIMENTAL"},{"label":"S40 EvoMab QM","type":"EXPERIMENTAL"}],"summary":"The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"A10 PBO Q2W","deltaMin":9.86,"sd":2.53},{"arm":"A10 PBO QM","deltaMin":0.97,"sd":2.82},{"arm":"A10 EZE (Q2W)","deltaMin":-21.96,"sd":2.63},{"arm":"A10 EZE (QM)","deltaMin":-17.08,"sd":2.78},{"arm":"A10 EvoMab Q2W","deltaMin":-61.56,"sd":1.81},{"arm":"A10 EvoMab QM","deltaMin":-58.19,"sd":1.99},{"arm":"A80 PBO Q2W","deltaMin":14.49,"sd":4.42},{"arm":"A80 PBO QM","deltaMin":11.83,"sd":3.85},{"arm":"A80 EZE (Q2W)","deltaMin":-14.6,"sd":4.29},{"arm":"A80 EZE (QM)","deltaMin":-19.8,"sd":3.85},{"arm":"A80 EvoMab Q2W","deltaMin":-61.8,"sd":3.04},{"arm":"A80 EvoMab QM","deltaMin":-58.68,"sd":2.74},{"arm":"R5 PBO Q2W","deltaMin":8.12,"sd":2.68},{"arm":"R5 PBO QM","deltaMin":5.1,"sd":2.62},{"arm":"R5 EvoMab Q2W","deltaMin":-60.09,"sd":1.94},{"arm":"R5 EvoMab QM","deltaMin":-59.4,"sd":1.87},{"arm":"R40 PBO Q2W","deltaMin":9.42,"sd":3.6},{"arm":"R40 PBO QM","deltaMin":2.59,"sd":4.3},{"arm":"R40 EvoMab Q2W","deltaMin":-58.89,"sd":2.58},{"arm":"R40 EvoMab QM","deltaMin":-52.4,"sd":2.98},{"arm":"S40 PBO Q2W","deltaMin":4.7,"sd":3.61},{"arm":"S40 PBO QM","deltaMin":3.4,"sd":4.94},{"arm":"S40 EvoMab Q2W","deltaMin":-65.86,"sd":3.05},{"arm":"S40 EvoMab QM","deltaMin":-57.02,"sd":3.93}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG001 vs OG005","p":"<0.001"},{"comp":"OG002 vs OG004","p":"<0.001"},{"comp":"OG003 vs OG005","p":"<0.001"},{"comp":"OG006 vs OG010","p":"<0.001"},{"comp":"OG007 vs OG011","p":"<0.001"},{"comp":"OG008 vs OG010","p":"<0.001"},{"comp":"OG009 vs OG011","p":"<0.001"},{"comp":"OG012 vs OG014","p":"<0.001"},{"comp":"OG013 vs OG015","p":"<0.001"},{"comp":"OG016 vs OG018","p":"<0.001"},{"comp":"OG017 vs OG019","p":"<0.001"},{"comp":"OG020 vs OG022","p":"<0.001"},{"comp":"OG021 vs OG023","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":244,"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","France","Germany","Hong Kong","Hungary","Italy","Mexico","Netherlands","Russia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["24825642","24481874","33325247","32564340","29736889","29353350","30755061","30120772","28249876","32114889","29768954","30852766"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Back pain","Headache","Muscle spasms","Myalgia","Diarrhoea"]}}